Industry-Supported Sessions

*All times are listed in EDT (UTC-4); all information as of press time*

Saturday, October 10

0800–0915
Symposium: Multidisciplinary Management of Early Stage Bladder Cancer

Chair: Peter Black, Canada
Faculty: Jürgen E. Gschwend, Germany
Shilpa Gupta, United States
Srikala Sridhar, Canada
Tilman Todenhöfer, Germany

At the end of this session, attendees will be able to:
• Review the most updated guidelines on NMBIC and MIBC
• Recognize the importance of risk stratification in the treatment decision-making for NMIBC and MIBC
• Review potential biomarkers to predict response to chemotherapy and immunotherapy in MIBC
• Analyze key data from clinical trials of IO and novel therapies in NMIBC, as well as emerging and combination therapies for MIBC
• Recognize the importance of a multidisciplinary team-based care planning for patients with early stage disease
• Outline immune-related adverse events and best practices for their mitigation and management

0800-0805
Welcome and Introductions
Peter Black

0805-0817
Evolving Treatment of High- Risk NMIBC
Tilman Todenhöfer, Germany

0817-0835
Case Presentation 1: BCG-unresponsive Case
Juergen Gschwend, Germany

0835-0847
New Paradigms in Multimodal Management of MIBC
Srikala Sridhar, Canada

0847-0905
Case Presentation 2: MIBC Case
Shilpa Gupta, United States

0905-0915
Take-Home Messages and Concluding Remarks
Peter Black

This session is supported by SIU Corporate Sponsor Bristol Myers Squibb.


1145–1300
Symposium: Up Close and Personal: Talking to your Patients about Overactive Bladder

Chair: Lysanne Campeau, Canada
Faculty: Dean Elterman, Canada
Stavros Gravas, Greece
Sender Herschorn, Canada

Case-based Panel Discussion
Dean Elterman, Stavros Gravas, Sender Herschorn

This session is supported by SIU Corporate Sponsor Astellas Pharma.

1900–2000
MC-02: MASTER CLASS: Genomic Testing and Recurrence in Prostate Cancer

Co-Chairs: Shusuke Akamatsu, Japan and Marc Dall’Era, United States
Moderator: Marc Dall’Era

At the end of this session, attendees will be able to:
• Recognize when to order genomic testing in prostate cancer treatment
• Determine who is expected to benefit from treatment with PARP inhibitors
• Explain the importance of genetic counseling
• State the current status and future prospect of liquid biopsy
Method: Lectures and discussion

1900–1912
The Role of Genomic Testing in Prostate Cancer
Vito Cucchiara, Italy

1912–1924
DNA Repair Gene Mutations and PARP Inhibitors in Prostate Cancer
Marc Dall’Era

1924–1936
Genetic Counselling in Prostate Cancer
Scott Eggener, United States

1936–1948
Liquid Biopsy in Prostate Cancer, Where Are We Now?
Shusuke Akamatsu

1948–2000
Debate and Q&A on Availability of Genetic Testing and Counselling in Each Region (USA, Italy, and
Japan, each representing North America, Europe and Asia)
All

This session is made possible by an unrestricted educational grant from Takeda Pharmaceutical Company

Sunday, October 11

0600–0700
IC-06: INSTRUCTIONAL COURSE 06: Urethral Stricture Surgery

Chair: Sanjay Kulkarni, India

0600-0605
Introduction
Sanjay Kulkarni, India

0605-0625
Bulbar Urethra Anastomotic, Dorsal and Ventral BMG, Non-Transection Bulbar Urethroplasty
Anthony Mundy, United Kingdom

0625-0645
Posterior Urethral Injury Acute Management and Delayed Treatment, Complex PFUI
Sanjay Kulkarni, India

0645-0658
Penile Urethroplasty
Guido Barbagli, Italy

0658-0700
Take Home Message
Sanjay Kulkarni, India

This session is made possible by an unrestricted educational grant provided from Sun Pharma.

0730-0830
The Future of IPP: The Art and Science of Meeting and Exceeding Patient Expectations

Chair: David Ralph,United Kingdom

At the conclusion of this activity, participants will be able
to:
• Consistently identify the best candidates for IPP
• Provide preoperative patient support and management that will optimize the likelihood that patients will be satisfied with their procedure
• Provide postoperative support that addresses common patient concerns and quickly identifies and manages complications, should they arise
• Keep your clinic running safely in the era of COVID-19

Panelists
Sebastien Beley, France
Tobias Kohler, United States
Koenraad van Renterghem, Belgium
Javier Romero-Otero, Spain

This session is supported by SIU Corporate Sponsor Coloplast.

1400–1530
IC-17: INSTRUCTIONAL COURSE: A Multidisciplinary Team Approach to the Treatment of Urothelial Carcinoma in the Age of Anti-PD1 Agents

Chair: Shaheen Alanee, United States

At the end of this session, attendees will be able to:
• Recognize the role of the multidisciplinary team (MDT) approach in the patient journey through treatment with immunotherapy for advanced bladder cancer
• Receive an introduction to systemic Immunotherapy in bladder cancer, Role of the MDT in identifying and managing immune-related side effects associated with anti-PD1 agents
• Understand the importance of interdisciplinary communication and education in preventing life-threatening complications
Method: Lectures and discussion

1400–1405
Course Introduction
Shaheen Alanee

1405–1425
Background on Bladder Cancer and Introduction to Anti-PD1 Agents
Shaheen Alanee

1425–1505
Benefits of MDT Approach for Patients Receiving Treatment with Anti PD Agents, and the Role of Anti-PD1 Agents in the Management of Locally Advanced and Metastatic Bladder Cancer
Petros Grivas, United States

1505–1530
Group Discussion

This session is made possible by an unrestricted educational grant from AstraZeneca.

Register Now B2B
Follow Us

Twitter feed
JOIN THE SIU COMMUNITY